Kura Oncology (KURA)
(Delayed Data from NSDQ)
$22.39 USD
+0.44 (2.00%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $22.40 +0.01 (0.04%) 4:22 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Brokerage Reports
Kura Oncology, Inc. [KURA]
Reports for Purchase
Showing records 101 - 120 ( 262 total )
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Early Clinical Proof of Concept for Tipi plus Alpelisib in HNSCC
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Our KURRENT View Starts Off Nice With First Clinical Look
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 102122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Previewing a Busy Q4: ASH Data Potential for Differentiation
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 101122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 10122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 92122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 91122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Time to Step Up for These Catalysts; Making Real Differences
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 9122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 82122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 81122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Zifotemenib RP2D Identified; Data Ahead
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Results; Ziftomenib's Top-Line Data Likely Key Driver at ASH''22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 8122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 72122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 71122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 7122
Provider: Stock Traders Daily
Analyst: Research Department